

Jaromir Hradec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1243620/publications.pdf>

Version: 2024-02-01

45
papers

18,430
citations

201385

27
h-index

264894

42
g-index

46
all docs

46
docs citations

46
times ranked

14764
citing authors

#	ARTICLE	IF	CITATIONS
1	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397.	13.9	3,337
2	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.	13.9	2,491
3	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). <i>Lancet</i> , The, 2003, 362, 782-788.	6.3	1,952
4	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	13.9	1,663
5	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1687-1713.	1.2	1,444
6	Rosuvastatin in Older Patients with Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2007, 357, 2248-2261.	13.9	1,330
7	ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1231-1265.	1.2	944
8	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2008, 372, 807-816.	6.3	934
9	European Society of Cardiology Heart Failure Long-term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year followâ€up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016, 18, 613-625.	2.9	538
10	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
11	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
12	Management of Grown Up Congenital Heart Disease. <i>European Heart Journal</i> , 2003, 24, 1035-1084.	1.0	446
13	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 1091-1099.	13.9	399
14	Expert consensus document on management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. <i>European Heart Journal</i> , 2003, 24, 761-781.	1.0	365
15	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2004, 110, 2618-2626.	1.6	347
16	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	3.8	297
17	Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Circulation</i> , 2009, 120, 2188-2196.	1.6	155
18	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial â€” FAT). <i>Cardiovascular Research</i> , 2001, 52, 290-298.	1.8	131

#	ARTICLE	IF	CITATIONS
19	Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (REDâ€œHF): a Phase III, anaemia correction, morbidityâ€œmortality trial. European Journal of Heart Failure, 2009, 11, 795-801.	2.9	107
20	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. Circulation, 2015, 131, 1486-1494.	1.6	92
21	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	2.9	75
22	<scp>ExtraHF</scp> survey: the first European survey on implementation of exercise training in heart failure patients. European Journal of Heart Failure, 2015, 17, 631-638.	2.9	69
23	Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin) Tj ETQq1 1 0.784314 rgBT /Overbo	0.7	82
24	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	1.0	53
25	Long-term echocardiographic follow-up of acromegalic heart disease. American Journal of Cardiology, 1993, 72, 205-210.	0.7	44
26	Valsartan and atenolol in patients with severe essential hypertension. Journal of Human Hypertension, 1998, 12, 563-567.	1.0	30
27	The Rationale and Design of the Perindopril Genetic Association Study (PERGENE): A Pharmacogenetic Analysis of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Stable Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2009, 23, 171-181.	1.3	27
28	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. American Heart Journal, 2003, 146, 110A-115A.	1.2	22
29	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure, 2010, 12, 66-74.	2.9	16
30	Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. Blood Pressure, 2006, 15, 302-307.	0.7	14
31	Czech Society of Cardiology Guidelines for the Diagnosis and Treatment of Chronic Heart Failure 2011. Cor Et Vasa, 2012, 54, e113-e134.	0.1	10
32	<i>Post hoc</i> analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Current Medical Research and Opinion, 2013, 29, 589-596.	0.9	9
33	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.0	8
34	Nitroglycerin Induced Syncope Occurs in Subjects with Delayed Phase Shift of Baroreflex Action. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 828-832.	0.5	7
35	Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study). American Journal of Cardiology, 2010, 105, 517-521.	0.7	5
36	Natriuretic peptides in heart failure. Cor Et Vasa, 2013, 55, e370-e376.	0.1	4

#	ARTICLE	IF	CITATIONS
37	Comparison of hospitalized and ambulatory patients with heart failure in the Czech Republic and Europe. Data from the ESC Heart Failure Long-Term Registry. <i>Cor Et Vasa</i> , 2015, 57, e6-e11.	0.1	2
38	The characteristics and drug therapy of patients with chronic systolic heart failure of ischemic etiology in the Czech Republic. <i>Cor Et Vasa</i> , 2009, 51, 268-273.	0.1	2
39	Septal aneurysm with associated anomalies. <i>Pediatric Radiology</i> , 1985, 15, 415-417.	1.1	1
40	Recurrent Peripheral Arterial Embolism from Metastatic Lung Choriocarcinoma. <i>Angiology</i> , 2006, 57, 127-129.	0.8	1
41	Summary of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Prepared by the Czech Society of Cardiology. <i>Cor Et Vasa</i> , 2013, 55, e25-e40.	0.1	1
42	Assessing cardiac patients for fitness to drive motor vehicles. Expert consensus statement of the Czech Society of Cardiology-2012 update. <i>Cor Et Vasa</i> , 2013, 55, e217-e224.	0.1	1
43	The effect of perindopril on arterial stiffness and endothelial function in patients with stable coronary artery disease. <i>Atherosclerosis</i> , 1999, 144, 54-55.	0.4	0
44	Comparison of clinical guidelines for the diagnosis and treatment of chronic heart failure of AĀEKS and ESC 2012. <i>Cor Et Vasa</i> , 2013, 55, e301-e308.	0.1	0
45	Comparison of therapy of heart failure patients in the Czech Republic and Europe. Data from the ESC Heart Failure Long-Term Registry. <i>Cor Et Vasa</i> , 2016, 58, e609-e614.	0.1	0